Citadel Advisors
NUVB icon

Citadel Advisors’s Nuvation Bio NUVB Stock Holding History

Citadel Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$318K Sell
74,200
-59,600
-45% -$332K ﹤0.01% 10341
2025
Q4 		$1.2M Buy
133,800
+112,200
+519% +$695K ﹤0.01% 6994
2025
Q3 		$79.9K Sell
21,600
-40,400
-65% -$110K ﹤0.01% 11973
2025
Q2 		$121K Buy
62,000
+57,400
+1,248% +$120K ﹤0.01% 11156
2025
Q1 		$8.1K Buy
4,600
+3,400
+283% +$7.74K ﹤0.01% 13662
2024
Q4 		$3.19K Sell
1,200
-2,000
-63% -$5.15K ﹤0.01% 14020
2024
Q3 		$7.33K Sell
3,200
-6,500
-67% -$19.8K ﹤0.01% 13368
2024
Q2 		$28.3K Sell
9,700
-30,900
-76% -$94.3K ﹤0.01% 12326
2024
Q1 		$148K Buy
40,600
+35,800
+746% +$68.7K ﹤0.01% 10787
2023
Q4 		$7.25K Sell
4,800
-19,900
-81% -$25.6K ﹤0.01% 13302
2023
Q3 		$33.1K Buy
24,700
+19,700
+394% +$32.8K ﹤0.01% 12198
2023
Q2 		$9K Buy
5,000
+4,900
+4,900% +$8.33K ﹤0.01% 13283
2023
Q1 		$166 Sell
100
-800
-89% -$1.62K ﹤0.01% 14558
2022
Q4 		$1.73K Buy
+900
New +$1.82K ﹤0.01% 14427
2021
Q4 		– Sell
-15,200
Closed -$151K – 14449
2021
Q3 		$151K Buy
+15,200
New +$138K ﹤0.01% 12373

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's NUVB Position: Q1 2026 in Review

Citadel Advisors increased its Nuvation Bio (NUVB) stake by 1,430% in Q1 2026, buying an estimated $10.8M and bringing the position to 2,065,411 shares worth $8.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3425.

Citadel Advisors first reported a position in NUVB in Q4 2020 and has held it in 22 quarters since. The position peaked at $68.8M in Q1 2021. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Citadel Advisors held 2,065,411 shares of Nuvation Bio worth $8.86M as of Q1 2026.
  • Citadel Advisors bought 1,930,412 Nuvation Bio shares in Q1 2026, an estimated $10.8M.
  • Nuvation Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3425 holding.
  • Citadel Advisors first reported a position in Nuvation Bio in Q4 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Nuvation Bio position peaked at $68.8M in Q1 2021.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.